Baxter Intl Inc Stock Price, News & Analysis

Baxter International Inc. (NYSE:BAX) presented significant data at Kidney Week 2022 demonstrating the benefits of its remote patient management platform, Sharesource, and the Theranova dialyzer. A controlled study revealed that Sharesource improves outcomes for home peritoneal dialysis patients by reducing adverse events. Additionally, ex vivo studies indicated that Theranova effectively removes larger middle-molecule toxins while maintaining albumin stability during hemodialysis. These innovations aim to enhance patient care in response to the global kidney disease crisis.

Baxter International reported third-quarter 2022 revenue of $3.8 billion, a 17% increase on a reported basis. U.S. GAAP EPS was ($5.83), reflecting $3.1 billion in impairment charges from the Hillrom acquisition, attributed to rising interest rates and equity declines. Adjusted EPS was $0.82, a 20% decrease year-over-year. International sales grew 1%, while U.S. sales surged 40%. Despite challenges from supply constraints and competition, Baxter's product innovations continue to drive growth. The company anticipates 17%-18% sales growth for the full year.

Baxter International Inc. (NYSE:BAX) will host a conference call on October 27, 2022, at 7:30 a.m. Central Time to discuss its third-quarter financial results. Interested participants can pre-register for the call via the provided link. The call will also be webcasted through Baxter’s official website, where it will be accessible after the live session. Baxter provides critical healthcare products across multiple sectors, serving patients globally. For more information, visit www.baxter.com.

Baxter International Inc. (NYSE:BAX) has announced a commitment of $400,000 to create scholarships aimed at increasing diversity in healthcare professions. This includes the establishment of the Baxter Nursing Scholars Award at Tennessee State University's School of Nursing and the Baxter Healthcare Scholarship at Howard University College of Pharmacy. The initiative is part of Baxter's Activating Change Today initiative to advance racial justice and support underrepresented Black students in health and sciences.

Baxter International (NYSE:BAX) has received FDA 510(k) clearance for its new Novum IQ syringe infusion pump, which features Dose IQ Safety Software. This advancement aims to enhance medication delivery safety, specifically for neonatal and pediatric patients. The Novum IQ SYR integrates seamlessly with hospital electronic medical records (EMRs) and incorporates advanced safety measures, including drug library access and titration error prevention. Baxter's IQ Enterprise Connectivity Suite allows for real-time infusion data and operating system upgrades, optimizing hospital resources.

Baxter International Inc. (NYSE:BAX) will present at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 10:25 a.m. Eastern Time. CFO Jay Saccaro is scheduled to discuss the company’s innovations and healthcare solutions. A live webcast of the presentation can be accessed at www.baxter.com and will be available for replay until February 23, 2023. Baxter has a 90-year history of providing critical healthcare products and services globally, impacting millions of patients and caregivers.

Baxter International Inc. (NYSE:BAX) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022. Jay Saccaro, Chief Financial Officer, is set to present at 10:35 a.m. Eastern Time. A live webcast of the presentation will be available on Baxter's website and can be replayed until March 13, 2023. Baxter has a long-standing history of providing essential medical products and innovations that improve healthcare across more than 100 countries.

Baxter International Inc. (NYSE:BAX) reported second-quarter 2022 revenue of $3.75 billion, marking a 21% increase on a reported basis and a 26% increase on a constant currency basis. U.S. GAAP EPS was $0.50, with adjusted EPS at $0.87. The company anticipates full-year sales growth in the high teens and forecasts U.S. GAAP EPS between $1.82 and $1.92. Despite operational challenges, including supply chain issues, Baxter's acquisition of Hillrom contributed significantly to performance, generating $715 million in sales.